Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Saw this. It still makes me question the recruitment of the current trial. Hopeful that there are enough patients on the milder scale to get the job done.
Looks like the neurofilament light data in collaboration with Biogen isn't quite imminent as today's PR says the coming weeks fyi.
Looks like the company has regained full Nasdaq compliance
Not sure the holdup on the neurofilament light data. Though it was supposed to be out in January
Tell it to the Cleveland Clinic. They are running the trial.
Bryostatin trial finally gets registered with details. Starts this month. 20 patients. Essentially same dosing as previous AD trial with 2 cycles and a follow up 12 weeks after final dose fyi.
https://classic.clinicaltrials.gov/ct2/show/NCT06190912?term=bryostatin&draw=2&rank=1
Quite a run today. Fingers crossed on the new data when released
Only what you can afford to lose. As risky as any.
I don't honestly know. It's seen huge profit taking every time they've put out positive news. Traders/shorters, who knows. The company needs money to advance and when that's the case you see wild swings. The ball is in Biogen's court it would seem. All depends on the biomarker results we should get at any time.
Yeah I don't like to see stuff like this at all but I sure pray the the drug is beneficial!
Potentially yes as long as some of the biomarker data is good. We should find out about that data in the next week or two supposedly to the best of my understanding.
I didn't see it but have read in the last week or so about the ultrasound waves aiding in plaque/tau reduction. What I had read had come out of West Virginia University where Bryostatin and Alkon had done much of their research so it could be a promising avenue. All that is dependent on how big of a problem plaque really is, which of course it up for debate. It's certainly interesting to follow and hopefully makes the anti-plaque drugs more effective with less side effect.
Congrats! After years of promoting an alternative AD play, you bailed out of that one many months ago I read. Maybe a wise move. These AD plays are difficult, especially with science that is hard to grasp. All these years and still not a single drug that can reverse the decline significantly. A real shame.
If Anavex hadn't dragged their feet so bad on the indication and allowed Acadia/Neuren to bring their drug to the market through a stat significant double in size trial, then maybe they could have still filed for approval just on a positive trend. Would seem more than unlikely now. Hopefully for Rett patients Kauffman can straighten things out and get another trial run if indeed Anavex has a better drug as many suppose. Real shame for the patients. I saw a Rett patient and her caregiver my wife has known for many years while shopping at a pet store yesterday. Such a great smile even if non communicative. Was really hoping for better results than this, especially in light of what Acadia is charging for their drug.
Yeah. That's a shame for them. You just never know, have to always diversify, and never gamble more than one can afford to lose. There are home runs out there. Just got to keep plugging away and take profits when they come. Merry Christmas!
It's had a nice move and you might be on to something. I've just never looked into that one. I did notice Neuren, which I've mentioned for years, keeps putting out great news in orphan indications and is sitting at around a 30 bagger with a similar drug to bryostatin but they turned from early AD research to orphan indications. You just never know. We missed the goal by not launching FragileX studies or even Rett IMO. GLTY
Absolutely
Yeah a little complicated but we'll see how much money that brings in. Could be enough to avoid raising before results...at least on any less than favorable terms. Very creative. No idea where the share price lands once it all plays out, but certainly a positive.
Got to love this warrant deal on multiple levels! Nice job management! Sure blew a hole in the "dead money" thesis when insiders were "propping up" the stock.
Strong follow through today again. This thing has made a lot of traders big money. Approximately 12 months to results. Can't get here soon enough
This is a post I made regarding ANVS 3-4 weeks ago Red. Keep in mind the stock has moved 50-60% since that post already.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173251789
Any news of why it's up almost 20% today?
You were off somewhere between 30% and 600%. Do you know how much a patient pays a year for ALS medication? That would be quite a bit of difference in sales revenues. Either way potential sales, if ever, are quite a ways off no doubt. If Biogen takes over the indication would likely be much quicker through any approval process. JMHO
You posted 1-3.
His facts were clearly wrong. Looks like Biogen could determine share price next year. Probably nothing to see here for the next 4-6 weeks imo
It's early in the process. I don't have a dog in the fight at this point but it's the Biogen connection that intrigues me as we await additional biomarker data.
Most likely yes but the company needs the cash to fund the P3 and this is a great opportunity with this volume. Fingers crossed for positive results
It's been a lost year for these guys. Some additional patents including ALS but no new trials launched. Hoping something gets launched next year for sake of the science
NRSN for the few that bought in. Results tomorrow AM. Most can easily take cost basis off the table. No idea of results as has always been risky and virtually nothing ever approved for ALS, but fingers crossed for the patients. GLTA
Couple new patents granted as company waits on shareholder approval to reverse split stock.
https://patents.justia.com/inventor/daniel-l-alkon
The filing spells it out. Its a couple million. Whether thats a waste or not, I have my opinion but these guys spend roughly 10 million a year. Some on licensing, a few employees salaries, and some on trials. It's hardly a get rich scheme. Of note the Cleveland Clinic had been paid 350k out of an estimated 2 million total for MS trial per 10q. With the holidays coming up, doesn't look like they will launch the trial before early next year. whether or not we get an update before then is getting less likely but you never know I guess. Likely some tax loss selling the next few weeks too.
Cash reserves won't drop. You're really reaching now. People have been claiming that for years but they always run a tight ship
I'm always hopeful in all these alternative plays as the SOC plaque attack drugs aren't worth the money
I had researched them in the past. In theory I liked their story about synaptic health and how the drug potentially worked. Preclinical it had a secondary impact on PKCe and Hgf and as you know, this is something I have researched. When I looked at details of how they were running their clinical trials I had concerns about the memantine free period before dosing so have never bought in. I still think they have a shot but maybe longer than I first thought. Of course at current prices it may be a better gamble than in the past.
I still follow the sector but I'm just not seeing a revolutionary treatment at this time. Doesn't mean none of these will have limited success, or potential approvals in some groups, or nice sales, or even make shareholders good money. I've been hoping for a true game changer and I don't currently see one. JMHO
Peeved, I've never been real big on this one but had hopes without following closely. This latest revelation really puts their credibility on the line
Quite a swing
It's bold and shameless but certainly not criminal and happens every day. Convertible debt almost always ends up in the crapper for shareholders.
That's why this hasn't been an investment for a very long time.Thats why reverse split was always going to take place once top line results weren't positive. Even though they have the money to run additional trials, it still isn't an investment at this point